New imaging agent RAD301 tested for safety in cancer patients

NCT ID NCT05799274

First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This early-stage study tests a new substance called RAD301 in 9 people—some healthy, some with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how RAD301 moves through the body and how much radiation reaches organs and tumors, and to check for side effects. It does not aim to treat the cancer, only to gather safety and imaging information.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • United Theranostics

    RECRUITING

    Princeton, New Jersey, 08540, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.